IPSEN (OTCMKTS:IPSEY) Sets New 52-Week High – Time to Buy?

IPSEN (OTCMKTS:IPSEY) reached a new 52-week high during trading on Wednesday . The company traded as high as $48.00 and last traded at $48.00, with a volume of 300 shares. The stock had previously closed at $46.30.

Wall Street Analysts Forecast Growth

IPSEY has been the subject of several research reports. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a research report on Tuesday, February 17th. UBS Group cut shares of IPSEN from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 8th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, IPSEN presently has an average rating of “Hold”.

IPSEN Stock Performance

The business has a 50-day moving average price of $43.74 and a 200 day moving average price of $38.32.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).